New drug trial aims to boost platelets in stubborn blood disorder
NCT ID NCT07196163
Summary
This study is testing an investigational drug called golidocitinib for adults with primary immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The trial has two parts: first to find a safe dose, and then to compare the drug against a placebo to see if it can effectively raise and maintain platelet counts. It is for adults whose ITP has not responded well to previous standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, 100010, China
Conditions
Explore the condition pages connected to this study.